Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNA, U5A small nuclear 6, pseudogene (RNU5A-6P) is a processed pseudogene derived from the U5A small nuclear RNA gene family, which is integral to the spliceosome—the ribonucleoprotein complex responsible for catalyzing pre-mRNA splicing in eukaryotic cells. The U5 snRNA plays a critical role in aligning exons for ligation during splicing; however, RNU5A-6P is annotated as a pseudogene, meaning it does not produce a functional RNA and is generally considered biologically inactive[1][3]. Pseudogenes like RNU5A-6P often arise via retrotransposition, where an RNA intermediate is reverse-transcribed and inserted into the genome, lacking regulatory elements and frequently carrying sequence truncations or mutations[3]. While some recent studies raise the possibility that certain snRNA pseudogenes might have regulatory potential under specific circumstances, this is only experimentally validated for a handful of pseudogenes and not for RNU5A-6P[1][5]. There is thus no evidence that RNU5A-6P encodes a receptor, enzyme, transporter, or any other conventional therapeutic target[1][3][5]. It does not serve as a biomarker or interact with drugs, nor is it associated with safety concerns or mechanisms of drug action. The parent U5A snRNA gene is essential for RNA splicing, and pathogenic variants in closely related snRNA genes (e.g., RNU5A-1, RNU5B-1) can cause rare neurological and developmental disorders due to defects in spliceosome function, but this does not apply to the pseudogene RNU5A-6P[1]. Pseudogenes occasionally generate noncoding RNAs (including siRNAs) that may exert regulatory roles, but these findings are rare, gene-specific, and not established for RNU5A-6P[5]. The presence of snRNA pseudogenes in the genome is mainly a consequence of historical retrotransposon activity (especially LINE-1 elements), contributing to genome architecture but not coding for functional molecules[3]. RNU5A-6P is a pseudogene copy of an RNA involved in the spliceosome, not a therapeutic target, and does not possess known biological or medical relevance beyond its status as a genetic artifact in the human genome. Its inclusion as a drug target or receptor would be incorrect and misleading according to current evidence[1][3][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U5A small nuclear 6, pseudogene (RNU5A-6P).